Masonic Cancer Center, University of Minnesota
The treatment plan is identical for all participants with the exception of the curcumin dose level that is assigned at study enrollment. Participants are instructed to take the curcumin and olive oil one after the other (order does not matter) twice a day on an empty stomach ideally 30 minutes before breakfast and dinner. Curcumin and high phenolic extra virgin olive oil (HP-EVOO) may continue for up to 12 months in the absence of unacceptable side effects.
Neurofibromatosis 1
curcumin, high phenolic extra virgin olive oil (HP-EVOO)
Phase 1
Study Type : | Interventional |
Estimated Enrollment : | 18 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | Study of Nutraceutical Intervention With High Phenolic Extra Virgin Olive Oil and Curcumin for Neurofibromatosis, Type 1 (NF1) |
Actual Study Start Date : | July 6, 2022 |
Estimated Primary Completion Date : | August 2024 |
Estimated Study Completion Date : | August 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Curcumin with high phenolic extra virgin olive oil (HP-EVOO) Identical for all participants with the exception of the curcumin dose level, which is assigned at study enrollment. |
Dietary Supplement: curcumin, high phenolic extra virgin olive oil (HP-EVOO) |
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States, 55455